Why FDA’s capitulation of genetic therapy is such a big deal

October 12, 2017, 7:32 PM|
On Thursday, an FDA advisory row gave the immature light for a therapy that could urge the prophesy of people who have a singular genetic commotion called Leber’s inborn amaurosis (LCA). CBS News medical writer Dr. Tara Narula weighs in.

Check Also

Remembering Chris Rosati, who widespread complacency while battling ALS

For the past 4 years, CBS News has been following a North Carolina man’s tour …

Leave a Reply

Your email address will not be published. Required fields are marked *